Sanofi-Aventis buys rights to insulin delivery tech

French drugmaker Sanofi-Aventis has bought the rights to a diabetes drug-delivery technology from Ascendis, an American and Danish pharmaceutical company. Sanofi says in a news release that the technology showed "promising results" with insulin in early tests.

Ascendis' technology, which it calls TransCon Linker, allows for precise, time-controlled, long-acting delivery of medication. It does this by creating transient bonds between larger molecules such as proteins and peptides, including insulin, and a carrier. The bonds allow for tailor-made release, according to the company, with no initial bursts.

Under the agreement, Sanofi will get the license to develop, manufacture and commercialize the technology in combination with active molecules for diabetes. Ascendis will receive an undisclosed upfront payment along with milestones.

- Bloomberg has the story
- and so does Dow Jones
- read the Sanofi press release

Suggested Articles

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.

Swiss scientists are using ultrasound to trap and deliver drugs in the brain, a non-invasive delivery method that could help target tumors, too.